Annotation Detail
Information
- Associated Genes
- BRAF
- Associated Variants
-
BRAF APC
BRAF APC - Associated Disease
- pancreatic cancer
- Source Database
- CIViC Evidence
- Description
- In a case report, a patient with pancreatic cancer harboring BRAF N486-P490del was treated with trametinib. Within 4 weeks of initiating therapy, her serum CA19-9 had fallen from 36,000 to 8,100 U/mL, and the radiographic partial response was revealed by CT at 8 weeks after initiation of trametinib. cfDNA measurements for BRAF and TP53 alleles revealed a dramatic decline in response to trametinib. After 6 months of therapy, radiographic progression was identified.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/7730
- Gene URL
- https://civic.genome.wustl.edu/links/genes/5
- Variant URL
- https://civic.genome.wustl.edu/links/variants/2794
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Pancreatic Cancer
- Evidence Direction
- Supports
- Drug
- Trametinib
- Evidence Level
- C
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 29903880
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Trametinib | Sensitivity | true |